PMID- 16426143
OWN - NLM
STAT- MEDLINE
DCOM- 20060314
LR  - 20181203
IS  - 1079-9907 (Print)
IS  - 1079-9907 (Linking)
VI  - 26
IP  - 1
DP  - 2006 Jan
TI  - Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine 
      gastroenteropancreatic carcinomas.
PG  - 8-13
AB  - Interferon-alpha (IFN-alpha) is well established in the treatment of 
      neuroendocrine carcinomas (NEC). Treatment is accompanied by fatigue and flu-like 
      symptoms. In patients with chronic hepatitis C, pegylated IFN (PEGIFN) leads to 
      improved antiviral efficacy and good tolerability. Our aim was to assess the 
      efficacy and tolerability of PEG-IFN on the management of patients with 
      well-differentiated NEC of the gastroenteropancreatic system. In 17 patients, the 
      effect of PEG-IFN-alpha2b was studied. After first-line octreotide treatment, 
      IFN-alpha was added at the time of tumor progression. Six patients were switched 
      from conventional IFN-alpha, and 11 patients were IFN naive. Inhibition of tumor 
      growth, including stabilization of disease, occurred in 13 of 17 patients, and 
      biochemical and symptomatic responses were seen in 7 of 10 patients with 
      functionally active tumors. Tolerability of PEG-IFN-alpha2b was much better than 
      that of IFN-alpha. Fatigue occurred in 59% of all patients but was mild in 
      severity. Eleven of thirteen patients who had a benefit remained on therapy for a 
      median time of 20 months (range 6-30 months). PEG-IFN-alpha2b provides 
      symptomatic and antiproliferative efficacy in patients with NEC. Better 
      tolerability of PEG-IFN-alpha2b improved patients' compliance, justifying its use 
      in patients who do not tolerate conventional IFN-alpha treatment.
FAU - Pavel, Marianne E
AU  - Pavel ME
AD  - Department of Medicine I, University Hospital Erlangen-Nuremberg, 91054 Erlangen, 
      Germany. marianne.pavel@med1.imed.uni-erlangen.de
FAU - Baum, Ulrich
AU  - Baum U
FAU - Hahn, Eckhart G
AU  - Hahn EG
FAU - Schuppan, Detlef
AU  - Schuppan D
FAU - Lohmann, Tobias
AU  - Lohmann T
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - United States
TA  - J Interferon Cytokine Res
JT  - Journal of interferon & cytokine research : the official journal of the 
      International Society for Interferon and Cytokine Research
JID - 9507088
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - G8RGG88B68 (peginterferon alfa-2b)
RN  - RWM8CCW8GP (Octreotide)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Carcinoma, Neuroendocrine/*drug therapy/pathology
MH  - Disease Progression
MH  - Female
MH  - Gastrointestinal Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Octreotide/therapeutic use
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Patient Compliance
MH  - Polyethylene Glycols
MH  - Recombinant Proteins
MH  - Treatment Outcome
EDAT- 2006/01/24 09:00
MHDA- 2006/03/15 09:00
CRDT- 2006/01/24 09:00
PHST- 2006/01/24 09:00 [pubmed]
PHST- 2006/03/15 09:00 [medline]
PHST- 2006/01/24 09:00 [entrez]
AID - 10.1089/jir.2006.26.8 [doi]
PST - ppublish
SO  - J Interferon Cytokine Res. 2006 Jan;26(1):8-13. doi: 10.1089/jir.2006.26.8.